Wacker Biosolutions to focus on biotechnology

Published: 2-Mar-2010
Manufacturing Ingredients Finance Pharmaceutical

Wacker Fine Chemicals becomes Wacker Biosolutions and concentrates on biotechnology

Wacker, the German chemical company, has changed the name of its Wacker Fine Chemicals division to Wacker Biosolutions as it gives the business a biotechnology focus.

Wacker Biosolutions will concentrate on building its business in three main areas, including pharmaceuticals, alongside its existing portfolio of fine chemicals and chemical intermediates. Its biotech products include cyclodextrins, cysteine and biologics, as well as fine chemicals and PVAc solid resins.

The Munich-based firm is currently extending process development and production capacities for the manufacture of pharmaceutical proteins at Wacker Biotech in Jena, Germany.

Wacker aims to offer tailored complete solutions to customers, taking advantage of the synergies between its chemical and biotech expertise. It sees potential in providing innovative products and technologies in the budding market for bioengineered products.

"This reorganisation lays further foundations for Wacker's future success in the growing field of biotechnology," said Gerhard Schmid, senior vice president of Wacker Biosolutions.

Over the past few years, Wacker has posted high double-digit growth with biotech products such as cyclodextrins and cysteine. The group sees future global-market potential in pharmaceutical actives, food additives and agrochemicals.

See more

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Read more
Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche

Trending Articles

  1. Strengthening US pharmaceutical supply: SCHOTT Pharma inaugurates expanded vial production in Lebanon, PA SCHOTT Pharma has inaugurated new production lines for both standard and sterile ready-to-use (RTU) glass vials designed to store a wide range of drugs — from biologics and other complex injectable therapies to vaccines and emergency room medications
  2. Compact, economical and sustainable cooling solutions for laboratories Huber Unichillers offer space-saving and environmentally friendly temperature control for research and industrial applications
  3. T-CURX acquires Pantherna Therapeutics to fast-track non-viral in vivo CAR-T pipeline Combining transposon-based CAR-T with Pantherna's LNP and mRNA platforms, T-CURX aims to accelerate clinical trials by a year and become Europe's first biotech with both technologies in-house
  4. Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb as part of ongoing strategic collaboration CRDMO successfully scaled and transferred Renaissance Pharma’s lead candidate, Daretabart a humanised monoclonal antibody targeting GD2 for high-risk neuroblastoma, in just 9 months
  5. Bruker announces major strides in 4D proteomics performance, further advances In intact and top-down functional proteoform analysis, and innovations in hybrid qual/quant 4D metabolomics All to enable deeper insights into disease biology. Bruker Also Launches Two Novel Mass Spectrometry Systems for Unique Applications in Energy Industry Research, and in Semiconductor Manufacturing

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

You may also like

Manufacturing

Lonza appoints Hans Trees as Global Head of Communications

Hans Trees will join Lonza as Global Head of Communications, Senior Vice President and Member of the Extended Executive Committee, effective 1 September 2026. Hans combines deep industry experience with a strong track record in stakeholder engagement, most recently serving as Global Head of External Engagement at Roche
Manufacturing

AlzeCure licenses Alzheimer’s candidate ACD680 to Lilly in deal worth up to $1bn

AlzeCure Pharma has entered a global licensing and collaboration agreement with Eli Lilly for its Alzheimer's disease candidate ACD680, securing a $10m upfront payment and potential milestone payments exceeding $1bn
Finance

GSK acquires Nuvalent for $10.6bn to accelerate NSCLC pipeline with FDA-reviewed ROS1 and ALK inhibitors

GSK has agreed to acquire clinical-stage oncology company Nuvalent for $10.6bn, securing two late-stage next-generation kinase inhibitors — zidesamtinib and neladalkib — currently under FDA review for potential 2026 approval in non-small cell lung cancer
Ingredients

Safe and accurate flow measurement for pharmaceutical production

Oval Gear (OG) meters from Titan Enterprises, fitted with a Namur sensor, provide consistent, accurate measurement across a wide range of liquids, from low-viscosity solvents to more viscous pharmaceutical ingredients
Finance

UK healthcare M&A drops 26% in Q1 2026 amid geopolitical tension and financing pressures

Heligan Group's latest report records just 53 deals, down from 72 in Q1 2025, with pharma and life sciences remaining most active despite tighter financing conditions and prolonged deal timelines
You need to be a subscriber to read this article.
Click here to find out more.
Finance

ADC funding, spatial biology investment and haematology M&A signal biopharma pipeline momentum

From a $86.6m Series B for first-in-class ADCs to a $1.25bn haematology acquisition, this week's deals reflect sustained biopharma investment in next-generation therapeutic platforms
Manufacturing

Safety in pharmaceutical manufacturing: why a trusted partner makes all the difference

By taking a three-tiered approach to protecting patients and personnel and ensuring plant compliance, GEA adopts a consultative approach to helping its customers navigate the responsibilities of pharmaceutical manufacturing safety with confidence
Subscribe now